Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient

Adjuvant treatment of operated melanoma has deeply changed in the last few years with the introduction of immune-checkpoint inhibitors and BRAF/MEK inhibitors. Sarcoidosis is a systemic inflammatory disease causing non-caseous granulomatous reactions. Sarcoid-like granulomatous reactions have been r...

Full description

Bibliographic Details
Main Authors: Andrea Boutros, Chiara Schiavi, Federica Cecchi, Francesco Spagnolo, Antonio Guadagno, Enrica Teresa Tanda, Francesca Giusti, Giuseppe Murdaca, Paola Queirolo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
melanoma
dabrafenib and trametinib
BRAF and MEK targeted therapy
immune-related adverse event irAE
immunotherapy
sarcoidosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.579523/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.579523/full

Similar Items